JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation.
Kröger
Nicolaus
N
Alchalby
Haefaa
H
Klyuchnikov
Evgeny
E
Badbaran
Anita
A
Hildebrandt
York
Y
Ayuk
Francis
F
Bacher
Ulrike
U
Bock
Oliver
O
Kvasnicka
Michael
M
Fehse
Boris
B
Zander
Axel
A
D000328:Adult; D020350:Graft vs Tumor Effect; D006801:Humans; D016219:Immunotherapy, Adoptive; D053614:Janus Kinase 2 / Q000235:genetics*; D008875:Middle Aged; D017354:Point Mutation; D055728:Primary Myelofibrosis / Q000503:physiopathology* / Q000628:therapy*; D012074:Remission Induction; D016879:Salvage Therapy; D033581:Stem Cell Transplantation; D014184:Transplantation, Homologous
C507924:JAK2 protein, human; D053614:Janus Kinase 2